Handelsbanken Fonder AB Has $317,000 Stake in Phreesia, Inc. (NYSE:PHR)

Handelsbanken Fonder AB increased its holdings in shares of Phreesia, Inc. (NYSE:PHR) by 23.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 12,600 shares of the company’s stock after purchasing an additional 2,400 shares during the period. Handelsbanken Fonder AB’s holdings in Phreesia were worth $317,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of PHR. R Squared Ltd acquired a new stake in Phreesia in the 4th quarter valued at $30,000. International Assets Investment Management LLC boosted its stake in Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after acquiring an additional 1,395 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Phreesia during the fourth quarter worth about $76,000. XTX Topco Ltd bought a new stake in shares of Phreesia during the third quarter worth $247,000. Finally, Intech Investment Management LLC bought a new stake in shares of Phreesia in the third quarter valued at about $316,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Stock Performance

NYSE PHR opened at $25.80 on Tuesday. The company has a market cap of $1.50 billion, a P/E ratio of -17.55 and a beta of 0.96. The company has a fifty day simple moving average of $27.51 and a 200 day simple moving average of $24.02. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. Phreesia’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.58) EPS. Sell-side analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Insider Activity at Phreesia

In other news, CFO Balaji Gandhi sold 28,759 shares of Phreesia stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $30.00, for a total transaction of $862,770.00. Following the sale, the chief financial officer now directly owns 116,174 shares in the company, valued at $3,485,220. The trade was a 19.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Evan Roberts sold 3,519 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $30.06, for a total transaction of $105,781.14. Following the transaction, the chief operating officer now owns 741,197 shares of the company’s stock, valued at approximately $22,280,381.82. The trade was a 0.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 195,740 shares of company stock valued at $5,441,409 over the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Robert W. Baird decreased their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Citigroup increased their target price on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research note on Friday, January 10th. JMP Securities reissued a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research note on Tuesday, December 10th. Finally, Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia has a consensus rating of “Buy” and a consensus target price of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.